APPENDIX 1A   |  APPENDIX 1B   |  APPENDIX 2A   |  APPENDIX 2B   |  APPENDIX 3   | 

 APPENDIX 4   |  APPENDIX 5   |  APPENDIX 6   |  APPENDIX 7   |  APPENDIX 8 | 

APPENDIX 7
Survival Using the Average of Covariates Method

The following are the Survival results using the average of covariates method (References 25, 26).

Figure Appendix 7.  Survival Distribution Function Compared Among Study Groups Using the Average of Covariates Method

Appendix 7 Figure Legends

Figure Appendix7.   Survival Distribution Function Compared Among Study Groups Using the Average of Covariates Method

Panel A: Adjusted survival distribution among 4345 patients by study group : control (1365 patients), aminocaproic acid (873 patients), tranexamic acid (821 patients), aprotinin (1286 patients).  Survival was significantly different between aprotinin and control (P < .001), but not between aminocaproic acid and control (P = .810), or between tranexamic acid and control (P = .641).  Survival was adjusted using the average of covariates method (see Methods). Patients participating in the in-hospital, but not long-term program were censored at 6 weeks.

Panel B: Adjusted survival distribution among patients without in-hospital death: control (1330 patients, aminocaproic acid (847 patients), tranexamic acid (804 patients), aprotinin (1229 patients). Survival was significantly different between aprotinin and control (P = .004), but not between aminocaproic acid and control (P = .558), or between tranexamic acid and control (P = .515).  Survival was adjusted using the average of covariates method (see Methods). Patients participating in the in-hospital, but not long-term program were censored at 6 weeks.